Seres Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Seres Therapeutics, Inc. (MCRB) reported Increase (Decrease) in Deferred Revenue of -$16.33 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-11-08
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-09-30 was -$8.46M.
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-06-30 was -$4.27M.
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$3.59M.
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$2.84M.
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2017 was -$11.89M, a 110.93% decline from fiscal 2016.
- Seres Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2016 was $108.81M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2018-09-30 | -$8.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$12.74M derived: sum of 2 quarters · filed 2018-11-08 | -$16.33M 10-Q · filed 2018-11-08 | -$19.17M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | -$4.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$7.86M 10-Q · filed 2018-08-02 | -$10.71M derived: sum of 3 quarters · filed 2018-08-02 | -$13.72M derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-03-31 | -$3.59M 10-Q · filed 2018-05-09 | -$6.44M derived: sum of 2 quarters · filed 2018-05-09 | -$9.45M derived: sum of 3 quarters · filed 2018-11-08 | -$12.46M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$5.86M derived: sum of 2 quarters · filed 2018-11-08 | -$8.87M derived: sum of 3 quarters · filed 2018-11-08 | -$11.89M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$6.03M derived: sum of 2 quarters · filed 2018-11-08 | -$9.04M 10-Q · filed 2018-11-08 | -$11.78M derived: sum of 4 quarters · filed 2018-11-08 |
| 2017-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$6.03M 10-Q · filed 2018-08-02 | -$8.76M derived: sum of 3 quarters · filed 2018-08-02 | -$11.60M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | -$3.02M 10-Q · filed 2018-05-09 | -$5.75M derived: sum of 2 quarters · filed 2018-05-09 | -$8.58M derived: sum of 3 quarters · filed 2018-05-09 | -$11.49M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$5.57M derived: sum of 2 quarters · filed 2018-03-08 | -$8.48M derived: sum of 3 quarters · filed 2018-03-08 | $108.81M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.75M derived: sum of 2 quarters · filed 2017-11-08 | $111.55M 10-Q · filed 2017-11-08 | |
| 2016-06-30 | -$2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $114.38M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $117.29M 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |